Adaptive Biotechnologies Corporation ADPT
Super Investor & Insider
2
Fondi che lo detengono
#452
Rank consenso
2.9%
% dei portafogli
$417.9M
Valore detenuto
| Fondo | % portaf. | Attività | Azioni | Valore |
|---|---|---|---|---|
| Viking Global Investors · Viking Global Investors | 1.16% | — | 29,993,708 | $416.3M |
| Polen Capital Management · Polen Capital Management | 0.01% | Reduce 64.38% | 116,051 | $1.6M |
Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.
About
Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company that develops an immune medicine platform for diagnosing and treating various diseases. The company's core offering is its immunosequencing platform, which uses proprietary chemistry, computational biology, and machine learning to generate…
SectorHealthcare
ExchangeNASDAQ
IndustryDiagnostics & Research
CountryUnited States
Employees624
TickerADPT
Statistics
Market Cap$2.64B
Revenue (TTM)$277.0M
Net Income-$59.5M
Net Margin-21.5%
EPS$-0.39
P/E-47.97
P/S10.15
P/B13.82
EV/EBITDA-91.64
ROE-24.0%
Dividend Yield—
Price$16.50
Data: Twelve Data · Revenue = mcap / P/S